Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline

by Ysios Capital

Ipsen announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody.

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Cómo empieza un desprendimiento de reti...

by Centro de Oftalmología Barraquer

El desprendimiento de retina suele comenzar con señales discretas per...

Photos Stream